Johnson & Johnson Potential Vaccine Rollout Faces Delays

Author:
Publish date:
Video Duration:
1:26

Johnson & Johnson’s (JNJ) - Get Report one-shot Covid-19 vaccine currently in late-stage trials is reportedly as much as two months behind the company's original production schedule, and won’t catch up until the end of April.

The New York Times reported Wednesday that while Johnson & Johnson expects to release results from its Covid-19 vaccine trial in as little as two weeks, production is likely facing hold-ups due to manufacturing delays.

The hold-up comes as the U.S. continues to face record infections, hospitalizations and deaths resulting from the novel coronavirus, which to date has infected some 91.6 million people, resulting in more than 1.96 million deaths, according to John Hopkins University. In the U.S., more than 4,300 people died from the disease on Tuesday, as the nation’s total death toll surpassed 380,000.

If Johnson & Johnson's vaccine can strongly protect people against Covid-19, as some outside scientists expect, it would offer big advantages over the two vaccines currently authorized in the U.S., which require two doses and more complicated cold-storage requirements.

Pfizer (PFE) - Get Report and BioNTech (BNTX) - Get Report as well as Moderna (MRNA) - Get Report were given emergency authorization to roll out their vaccines last month. 

Latest Videos From TheStreet and Jim Cramer: